Completed
A strategy for selectively stable lipid nanoparticles: interbilayer-crosslinked multilamellar vesicles (CMV)
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
New Approaches to Vaccine Development for TB and HIV
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 2 classes of successful, licensed vaccines
- 3 Liposomes: the prototypical particulate delivery system
- 4 A strategy for selectively stable lipid nanoparticles: interbilayer-crosslinked multilamellar vesicles (CMV)
- 5 (1) Stabilized lipid capsules deliver antigen to lymph node cells more efficiently than soluble or liposomal vaccines
- 6 ICMV nanocapsules elicit long-lived, high avidity humoral responses using low doses of antigen
- 7 Needle-free mucosal vaccination with ICMVS
- 8 Establishment of large mucosa-localized effector memory T- cell populations
- 9 Vaccination: Location, location, location
- 10 A clinically validated strategy for LN targeting: sentinel lymph node mapping
- 11 albumin hitch-hiking keeps CpG at local immune induction site avoiding systemic inflammation
- 12 Applying the amphiphile vaccine to HIV Designing long peptide antigens to constrain viral fitness
- 13 lymph node targeting amphiphiles as a strategy to maximize the efficacy and safety of a sector peptide-based vaccine
- 14 Acknowledgments
